COMT and cancer: Castel and colleagues reviewed genetic, inflammatory, and hematologic biomarkers across several cancer types (excluding brain tumors and metastases), identifying associations primarily with genetic polymorphisms (APOE-4 and COMT-Val), inflammatory cytokines (IL-6), anemia, and alterations in hypothalamic–pituitary–adrenal axis hormones [25].